Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control
This study is currently recruiting participants.
Verified December 2012 by Rocky Mountain MS Research Group, LLC
Sponsor:
John F. Foley, MD
Collaborators:
Biogen Idec
Elan Pharmaceuticals
Information provided by (Responsible Party):
John F. Foley, MD, Rocky Mountain MS Research Group, LLC
ClinicalTrials.gov Identifier:
NCT01626248
First received: June 20, 2012
Last updated: December 14, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | April 2013 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |